Prime Medicine logo

Prime Medicine

Cambridge, MA

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.

https://primemedicine.com/

Company Details

Founded

2019

Employees

214 employees

Raised

$553,200,000

Headquarters Location

Cambridge, MA

Public

Yes

Acquired

No

CEO

Allan ReineAllan Reine

Founders

David R. Liu
David R. Liu
Andrew Anzalone
Andrew Anzalone

Company Collections

These are collections Prime Medicine is a part of. Click on the collection name to view similar companies.

Current Job Listings

Listing 0 of 19 job openings

    Prime Medicine Headquarters Location

    21 Erie Street, Cambridge, MA 02139

    Total Amount Raised: $553,200,000

    Prime Medicine's Investors

    Prime Medicine Funding Rounds

    • Post Ipo Equity

      $144,200,000

    • Post Ipo Equity

      $24,000,000

      Post Ipo Equity Investors

      Cystic Fibrosis Foundation
    • Corporate Round

      $55,000,000

      Corporate Round Investors

      Bristol-Myers Squibb Company
    • Undisclosed

      $15,000,000

      Undisclosed Investors

      Cystic Fibrosis Foundation
    • IPO

      Unknown

    • Series B

      $200,000,000

      Series B Investors

      GV
      PSP Investments
      Redmile Group
      Newpath Partners
      Samsara BioCapital
      Cormorant Asset Management
      Arch Venture Partners
      Moore Strategic Ventures
      F-Prime Capital
      T. Rowe Price
      Casdin Capital
      Arrive
    • Series A

      $115,000,000

      Series A Investors

      Arch Venture Partners
      F-Prime Capital
      GV
      Newpath Partners
      Arrive
    Funding info provided by Diffbot.

    Prime Medicine Reviews

    0 out of 5 stars

    Based on 0 reviews

    Review data

    Share your thoughts

    Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Prime Medicine.

    Recent reviews